Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling

Oncotarget

Volumn 7, Issue 21, 2016, Pages 31413-31428

  Tong, Yunli ^a,b   Liu, Yuting ^a,b   Zheng, Hongming ^b   Zheng, Liang ^a,b   Liu, Wenqin ^a,b   Wu, Jinjun ^b   Ou, Rilan ^b   Zhang, Guiyu ^b   Li, Fangyuan ^b   Hu, Ming ^b,c   Liu, Zhongqiu ^a,b   Lu, Linlin ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^c UNIVERSITY OF HOUSTON   (United States)

Author keywords

Artemisinin; Derivative; Non small cell lung cancer; Wnt catenin

Indexed keywords

AFATINIB; ARTEMISININ; ARTESUNATE; AXIS INHIBITION PROTEIN; BETA CATENIN; DIHYDROARTEMISININ; NAKED CUTICLE 2 PROTEIN; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN; WNT5A PROTEIN; WNT5B PROTEIN; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG CANCER CELL LINE; METASTASIS; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; SIGNAL TRANSDUCTION; A-549 CELL LINE; ANIMAL; BAGG ALBINO MOUSE; CELL CYCLE CHECKPOINT; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENETICS; LUNG TUMOR; METABOLISM; NUDE MOUSE; RNA INTERFERENCE; TUMOR CELL LINE; WNT SIGNALING;

A549 CELLS; ANIMALS; ANTIMALARIALS; ARTEMISININS; BETA CATENIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINTS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; LUNG NEOPLASMS; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; RNA INTERFERENCE; WNT SIGNALING PATHWAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84971570070     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8920     Document Type: Article

References (54)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87-108.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
3. Gridelli C, Rossi A and Maione P. The potential role of histone deacetylase inhibitors in the treatment of nonsmall-cell lung cancer. Critical reviews in oncology/hematology. 2008; 68:29-36.
4. Stella GM, Luisetti M, Pozzi E and Comoglio PM. Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics. The Lancet Respiratory medicine. 2013; 1:251-261.
5. Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG. Cancer drug resistance: an evolving paradigm. Nature reviews Cancer. 2013; 13:714-726.
6. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nature reviews Cancer. 2003; 3:768-780.
7. Stewart DJ, Chang DW, Ye Y, Spitz M, Lu C, Shu X, Wampfler JA, Marks RS, Garces YI, Yang P and Wu X. Wnt signaling pathway pharmacogenetics in non-small cell lung cancer. The pharmacogenomics journal. 2014; 14:509-522.
8. Liu D, Li L, Yang Y, Liu W and Wu J. The Axin2 rs2240308 polymorphism and susceptibility to lung cancer in a Chinese population. Tumour biology. 2014; 35:10987-10991.
9. Hu T, Li C, Cao Z, Van Raay TJ, Smith JG, Willert K, Solnica-Krezel L and Coffey RJ. Myristoylated Naked2 antagonizes Wnt-beta-catenin activity by degrading Dishevelled-1 at the plasma membrane. The Journal of biological chemistry. 2010; 285:13561-13568.
10. Kishida S, Yamamoto H, Hino S, Ikeda S, Kishida M and Kikuchi A. DIX domains of Dvl and axin are necessary for protein interactions and their ability to regulate betacatenin stability. Molecular and cellular biology. 1999; 19:4414-4422.
11. Bravo DT, Yang YL, Kuchenbecker K, Hung MS, Xu Z, Jablons DM and You L. Frizzled-8 receptor is activated by the Wnt-2 ligand in non-small cell lung cancer. BMC cancer. 2013; 13:316.
12. Wang C, Yang W, Yan HX, Luo T, Zhang J, Tang L, Wu FQ, Zhang HL, Yu LX, Zheng LY, Li YQ, Dong W, He YQ, Liu Q, Zou SS, Lin Y, et al. Hepatitis B virus X (HBx) induces tumorigenicity of hepatic progenitor cells in 3, 5-diethoxycarbonyl-1, 4-dihydrocollidine-treated HBx transgenic mice. Hepatology. 2012; 55:108-120.
13. You Z, Saims D, Chen S, Zhang Z, Guttridge DC, Guan KL, MacDougald OA, Brown AM, Evan G, Kitajewski J and Wang CY. Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. The Journal of cell biology. 2002; 157:429-440.
14. Okita K and Yamanaka S. Intracellular signaling pathways regulating pluripotency of embryonic stem cells. Current stem cell research & therapy. 2006; 1:103-111.
15. Pan G and Thomson JA. Nanog and transcriptional networks in embryonic stem cell pluripotency. Cell research. 2007; 17:42-49.
16. Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF and Huelsken J. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature. 2012; 481:85-89.
17. Subramaniam G, Campsteijn C and Thompson EM. Co-expressed Cyclin D variants cooperate to regulate proliferation of germline nuclei in a syncytium. Cell cycle. 2015; 14:2129-2141.
18. Douchi D, Ohtsuka H, Ariake K, Masuda K, Kawasaki S, Kawaguchi K, Fukase K, Oikawa M, Motoi F, Naitoh T, Katayose Y, Egawa S and Unno M. Silencing of LRRFIP1 reverses the epithelial-mesenchymal transition via inhibition of the Wnt/beta-catenin signaling pathway. Cancer letters. 2015; 365:132-140.
19. Holcombe RF, Martinez M, Planutis K and Planutiene M. Effects of a grape-supplemented diet on proliferation and Wnt signaling in the colonic mucosa are greatest for those over age 50 and with high arginine consumption. Nutrition journal. 2015; 14:62.
20. Bi X, Zhao Y, Fang W and Yang W. Anticancer activity of Panax notoginseng extract 20(S)-25-OCH3-PPD: Targetting beta-catenin signalling. Clinical and experimental pharmacology & physiology. 2009; 36:1074-1078.
21. Zhao Y, Yao J, Wu XP, Zhao L, Zhou YX, Zhang Y, You QD, Guo QL and Lu N. Wogonin suppresses human alveolar adenocarcinoma cell A549 migration in inflammatory microenvironment by modulating the IL-6/STAT3 signaling pathway. Molecular carcinogenesis. 2015; 54 Suppl 1:E81-93.
22. Dragnev K, You M, Wang Y and Lubet R. Lung cancer chemoprevention: difficulties, promise and potential agents? Expert opinion on investigational drugs. 2013; 22:35-47.
23. Qian X, Song JM, Melkamu T, Upadhyaya P and Kassie F. Chemoprevention of lung tumorigenesis by intranasally administered diindolylmethane in A/J mice. Carcinogenesis. 2013; 34:841-849.
24. Efferth T, Dunstan H, Sauerbrey A, Miyachi H and Chitambar CR. The anti-malarial artesunate is also active against cancer. International journal of oncology. 2001; 18:767-773.
25. Eastman RT and Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nature reviews Microbiology. 2009; 7:864-874.
26. Dondorp AM, Fairhurst RM, Slutsker L, Macarthur JR, Breman JG, Guerin PJ, Wellems TE, Ringwald P, Newman RD and Plowe CV. The threat of artemisinin-resistant malaria. The New England journal of medicine. 2011; 365:1073-1075.
27. Kakuru A, Jagannathan P, Muhindo MK, Natureeba P, Awori P, Nakalembe M, Opira B, Olwoch P, Ategeka J, Nayebare P, Clark TD, Feeney ME, Charlebois ED, Rizzuto G, Muehlenbachs A, Havlir DV, et al. Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy. The New England journal of medicine. 2016; 374:928-939.
28. Nji AM, Ali IM, Moyeh MN, Ngongang EO, Ekollo AM, Chedjou JP, Ndikum VN, Evehe MS, Froeschl G, Heumann C, Mansmann U, Ogundahunsi O and Mbacham WF. Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunateamodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children. Malaria journal. 2015; 14:27.
29. Karunajeewa HA, Manning L, Mueller I, Ilett KF and Davis TM. Rectal administration of artemisinin derivatives for the treatment of malaria. Jama. 2007; 297:2381-2390.
30. Batty KT, Davis TM, Thu LT, Binh TQ, Anh TK and Ilett KF. Selective high-performance liquid chromatographic determination of artesunate and alpha-and betadihydroartemisinin in patients with falciparum malaria. Journal of chromatography B, Biomedical applications. 1996; 677:345-350.
31. Titulaer HA, Zuidema J, Kager PA, Wetsteyn JC, Lugt CB and Merkus FW. The pharmacokinetics of artemisinin after oral, intramuscular and rectal administration to volunteers. The Journal of pharmacy and pharmacology. 1990; 42:810-813.
32. Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS and Fleckenstein L. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malaria journal. 2011; 10:263.
33. Chen T, Li M, Zhang R and Wang H. Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. Journal of cellular and molecular medicine. 2009; 13:1358-1370.
34. Wang SJ, Gao Y, Chen H, Kong R, Jiang HC, Pan SH, Xue DB, Bai XW and Sun B. Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer letters. 2010; 293:99-108.
35. Gomes MF, Faiz MA, Gyapong JO, Warsame M, Agbenyega T, Babiker A, Baiden F, Yunus EB, Binka F, Clerk C, Folb P, Hassan R, Hossain MA, Kimbute O, Kitua A, Krishna S, et al. Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebocontrolled trial. Lancet. 2009; 373:557-566.
36. Rasheed SA, Efferth T, Asangani IA and Allgayer H. First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. International journal of cancer. 2010; 127:1475-1485.
37. Odaka Y, Xu B, Luo Y, Shen T, Shang C, Wu Y, Zhou H and Huang S. Dihydroartemisinin inhibits the mammalian target of rapamycin-mediated signaling pathways in tumor cells. Carcinogenesis. 2014; 35:192-200.
38. Field JK, Oudkerk M, Pedersen JH and Duffy SW. Prospects for population screening and diagnosis of lung cancer. Lancet. 2013; 382:732-741.
39. Schramm A, De Gregorio N, Widschwendter P, Fink V and Huober J. Targeted Therapies in HER2-Positive Breast Cancer-a Systematic Review. Breast care (Basel, Switzerland). 2015; 10:173-178.
40. Kramer R, Bielawski J, Kistner-Griffin E, Othman A, Alecu I, Ernst D, Kornhauser D, Hornemann T and Spassieva S. Neurotoxic 1-deoxysphingolipids and paclitaxelinduced peripheral neuropathy. FASEB journal. 2015; 29:4461-4472.
41. Das AK. Anticancer Effect of AntiMalarial Artemisinin Compounds. Annals of medical and health sciences research. 2015; 5:93-102.
42. Gordi T and Lepist EI. Artemisinin derivatives: toxic for laboratory animals, safe for humans? Toxicology letters. 2004; 147:99-107.
43. Toovey S. Safety of artemisinin antimalarials. Clinical infectious diseases. 2006; 42:1214-1215.
44. Clark RL. Embryotoxicity of the artemisinin antimalarials and potential consequences for use in women in the first trimester. Reproductive toxicology. 2009; 28:285-296.
45. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. The Lancet Oncology. 2012; 13:239-246.
46. Rosell R, Bivona TG and Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet. 2013; 382:720-731.
47. Camarillo JM, Rose KL, Galligan JJ, Xu S and Marnett LJ. Covalent Modification of CDK2 by 4-Hydroxynonenal as a Mechanism of Inhibition of Cell Cycle Progression. Chemical research in toxicology. 2016; 29:323-332.
48. Roskoski R, Jr. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs. Pharmacological research. 2016.
49. Szabo E, Mao JT, Lam S, Reid ME and Keith RL. Chemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143:e40S-60S.
50. Hubaux R, Thu KL and Lam WL. Re: the Wnt signaling pathway in non-small cell lung cancer. Journal of the National Cancer Institute. 2014; 106.
51. Peng YY, He YH, Chen C, Xu T, Li L, Ni MM, Meng XM, Huang C and Li J. NLRC5 regulates cell proliferation, migration and invasion in hepatocellular carcinoma by targeting the Wnt/beta-catenin signaling pathway. Cancer letters. 2016.
52. Bartis D, Csongei V, Weich A, Kiss E, Barko S, Kovacs T, Avdicevic M, D'Souza VK, Rapp J, Kvell K, Jakab L, Nyitrai M, Molnar TF, Thickett DR, Laszlo T and Pongracz JE. Down-regulation of canonical and up-regulation of non-canonical Wnt signalling in the carcinogenic process of squamous cell lung carcinoma. PloS one. 2013; 8:e57393.
53. Xu H, Tsang KS, Wang Y, Chan JC, Xu G and Gao WQ. Unfolded protein response is required for the definitive endodermal specification of mouse embryonic stem cells via Smad2 and beta-catenin signaling. The Journal of biological chemistry. 2014; 289:26290-26301.
54. Bowman AN, van Amerongen R, Palmer TD and Nusse R. Lineage tracing with Axin2 reveals distinct developmental and adult populations of Wnt/beta-catenin-responsive neural stem cells. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110:7324-7329.